The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients

British Journal of Cancer

Volumn 112, Issue 9, 2015, Pages 1527-1535

  Mavridis, K ^a   Gueugnon, F ^b   Petit Courty, A ^b   Courty, Y ^b   Barascu, A ^b   Guyetant, S ^b   Scorilas, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Université Franaois Rabelais   (France)

Author keywords

lung cancer; microRNAs; miR 197; overall survival; prognostic biomarker; stage I NSCLC

Indexed keywords

MICRORNA; MICRORNA 197; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN197 MICRORNA, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FOLLOW UP; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SMOKING; SPECTROPHOTOMETRY; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; ADENOCARCINOMA; AGED; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; LUNG; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICRORNAS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84928755784     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.119     Document Type: Article

References (59)

1. Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. (2013). Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys 67(3): 875-884
2. Boeri M, Pastorino U, Sozzi G. (2012). Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 18(3): 268-274
3. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 108(9): 3713-3718
4. Camp RL, Dolled-Filhart M, Rimm DL. (2004). X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21): 7252-7259
5. Chen L, Li C, Peng Z, Zhao J, Gong G, Tan D. (2013). miR-197 expression in peripheral blood mononuclear cells from hepatitis B virus-infected patients. Gut Liver 7(3): 335-342
6. Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, Suh KS. (2013). MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta 34(9): 799-804
7. Dai N, Zhong ZY, Cun YP, Qing Y, Chen C, Jiang P, Li MX, Wang D. (2013). Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 60(4): 384-394
8. Dai W, Wang C, Wang F, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Yang J, Zhu R, Zhang H, Li J, Zheng Y, Lu J, Zhou Y, Xu L, Guo C. (2014). Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem Biophys Res Commun 446(2): 541-548
9. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A. (2009). miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 7(8): 1234-1243
10. Duffy MJ, Crown J. (2008). A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54(11): 1770-1779
11. Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V, Younossi ZM. (2010). Differential expression of miRNAs in the visceral adipose tissue of patients with non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 32(3): 487-497
12. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, De Maria R. (2014). Antitumor effect of miR-197 targeting in p53 wild-Type lung cancer. Cell Death Differ 21(5): 774-782
13. Gadgeel SM, Ramalingam SS, Kalemkerian GP. (2012). Treatment of lung cancer. Radiol Clin North Am 50(5): 961-974
14. Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R. (2008). A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol 31(1): 22-28
15. Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, Kikuta K, Kume K, Unno J, Egawa S, Motoi F, Unno M, Shimosegawa T. (2013). miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228(6): 1255-1263
16. Jernas M, Malmestrom C, Axelsson M, Nookaew I, Wadenvik H, Lycke J, Olsson B. (2013). MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol 14: 32
17. Johnson DH, Schiller JH, Bunn Jr. PA. (2014). Recent clinical advances in lung cancer management. J Clin Oncol 32(10): 973-982
18. Jones R, Payne B. (1997). Clinical Investigation and Statistics in Laboratory Medicine. ACB Venture Publications: London
19. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF, Jeyaseelan K. (2012). Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97(12): E2271-E2276
20. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O, Fahey III TJ. (2012). A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 18(7): 2032-2038
21. Laios A, OToole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, DArcy T, McGuinness E, Sheils O, Sheppard B, OLeary J. (2008). Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35
22. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH, Langer F. (2010). Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 10: 109
23. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B, Pavlotsky F, Barshack I, Polak-Charcon S, Orenstein A, Hornstein E, Sidi Y, Avni D. (2011). MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 6(6): e20916
24. Leung F, Diamandis EP, Kulasingam V. (2012). From bench to bedside: discovery of ovarian cancer biomarkers using high-Throughput technologies in the past decade. Biomark Med 6(5): 613-625
25. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K, Daiming F. (2011). miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9(7): 824-833
26. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. (2014). Epigenetic biomarkers in lung cancer. Cancer Lett 342(2): 200-212
27. Lin J, Beer DG. (2012). Molecular predictors of prognosis in lung cancer. Ann Surg Oncol 19(2): 669-676
28. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagavathi S, Greiner TC, Weisenburger DD, Aoun P, Perkins SL, McKeithan TW, Inghirami G, Chan WC. (2013). MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 122(12): 2083-2092
29. Maes OC, Chertkow HM, Wang E, Schipper HM. (2009). MicroRNA: implications for alzheimer disease and other human CNS disorders. Curr Genomics 10(3): 154-168
30. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109(1): 120-129
31. Mavridis K, Stravodimos K, Scorilas A. (2013). Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 59(1): 261-269
32. Minguzzi S, Selcuklu SD, Spillane C, Parle-McDermott A. (2014). An NTD-Associated polymorphism in the 30 UTR of MTHFD1L can affect disease risk by altering miRNA binding. Hum Mutat 35(1): 96-104
33. Nana-Sinkam SP, Croce CM. (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93(1): 98-104
34. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. (2008). MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93(5): 1600-1608
35. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, Ueno Y, Nakayama K, Shimosegawa T. (2013). Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One 8(6): e66086
36. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. (2010). MicroRNA expression variability in human cervical tissues. PLoS One 5(7): e11780
37. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. (2012). Metastatic nonsmall-cell lung cancer (NSCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7): vii56-vii64
38. Powell CA, Halmos B, Nana-Sinkam SP. (2013). Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med 188(2): 157-166
39. Qi Y, Zhu Z, Shi Z, Ge Y, Zhao K, Zhou M, Cui L. (2014). Dysregulated microRNA expression in serum of non-vaccinated children with varicella. Viruses 6(4): 1823-1836
40. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. (2013). Management of non-small-cell lung cancer: recent developments. Lancet 382(9893): 709-719
41. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. (2012). Downregulation of the tumor-suppressor miR-16 via progestinmediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 14(3): R77
42. Shen J, Jiang F. (2012). Applications of microRNAs in the diagnosis and prognosis of lung cancer. Expert Opin Med Diagn 6(3): 197-207
43. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64(11): 3753-3756
44. Vannini I, Fanini F, Fabbri M. (2013). MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem 46(10-11): 918-925
45. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S. (2013). Early and locally advanced non-small-cell lung cancer (NSCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6): vi89-vi98
46. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7): 2257-2261
47. Wang P, Li Y, Hong W, Zhen J, Ren J, Li Z, Xu A. (2012). The changes of microRNA expression profiles and tyrosinase related proteins in MITF knocked down melanocytes. Mol Biosyst 8(11): 2924-2931
48. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K, Soteropoulos P, Wei JJ. (2007). A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46(4): 336-347
49. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. (2006). A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 91(9): 3584-3591
50. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. (2008). Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14(9): 2588-2592
51. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3): 189-198
52. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY, Zhang C (2013) Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132(1): 116-127
53. Yang Y, Li YX, Yang X, Jiang L, Zhou ZJ, Zhu YQ (2013) Progress risk assessment of oral premalignant lesions with saliva miRNA analysis. BMC Cancer 13: 129
54. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107(6): 810-817
55. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. (2012). Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 60(4): 290-299
56. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX. (2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4(6): 575-586
57. Zhou J, Zheng Q, Xu T, Liao D, Zhang Y, Yang S, Hu J. (2014). Associations between physical activity-related miRNAs and metabolic syndrome. Horm Metab Res 46(3): 201-205
58. Zhou J, Zhou Y, Yin B, Hao W, Zhao L, Ju W, Bai C (2010) 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol Rep 23(1): 121-128
59. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS. (2010). Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28(29): 4417-4424